medic devic nutrit busi take lead
maintain buy rate upgrad tp
provid upsid potenti
deriv estim base forward earn
multipl ep estim top-lin
revenu grow
base estim number factor continu
strong growth medic devic diagnost busi
improv perform nutrit busi outstand
product new product line acquisit aler
complet
abbott deliv strong result posit compani
long term sustain organ growth net revenu increas
due continu strong growth medic devic busi
improv perform nutrit busi abbott total revenu
increas compar
segment revenu nutrit segment revenu increas
report basi compar
medic devic segment revenu increas
compar previou year quarter
diagnost segment revenu increas
compar establish
pharmaceut revenu increas
gross margin compar
non-gaap gross margin revenu
compar net earn
non-gaap net earn compar
compani nametickerabtstock ratingbuyunchangedindustri viewoverweightpositivepric june week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispidearavindra june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
gaap ep compar
non-gaap ep increas
compar
januari abbott announc fda approv magnet
reson mr -condit label quadra assura
quadra assura mptm cardiac resynchron therapi
defibril crt-d devic fortifi
implant cardiovert defibril
approv abbott mr-condit label suit
pacemak crt-d devic
januari abbott announc free style libr abbott
system avail approv coverag
 center medicar medicaid servic
march abbott announc clinic trial data
momentum studi demonstr heartmat
left ventricular assist devic lvad improv surviv
clinic outcom two year patient advanc
guidanc abbott project adjust ep
ep
organ sale growth forecast
abbott price-to-earnings averag
price-to-earnings multipl improv went
current expect forward price-to-earnings
multipl give buy rate
stock upgrad tp
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date may ex-dividend date apr last split factor new per last split date jan inform abbott laboratori june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
incom statement item total gross research develop sell gener administr sg oper oper profit interest incom special charges- interest incom minor incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli june
 market account receivable- total prepaid current total current build machineri furnitur total fix non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom taxes- non-curr liabilities- minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item abbott laboratori june
net cash oper activ increas prior year
due higher segment oper earn continu improv work capit manag
time pension contribut lower acquisition-rel expens
reduct cash cash equival decemb march
primarili reflect repay debt payment dividend partial off-set cash gener
oper quarter work capit march decemb
decreas work capit primarili due reduct cash
defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end june
abbott deliv strong result due continu strong growth
medic devic busi improv perform nutrit busi
strong perform also due outstand product abbott new
abbott total revenu increas compar
organ basi revenu increas compar
previou year quarter total product revenu increas
compar busi revenu
total revenu increas compar
total intern revenu increas
compar net growth revenu due
acquisit aler close well growth abbott
busi exclud impact foreign exchang
cog first quarter compar previou year
gross margin compar non-gaap
gross margin revenu compar
increas reflect favor comparison versu prior year includ
inventori step-up amort relat st jude medic acquisit
increas also reflect margin improv variou busi includ diabet
cardiovascular neuromodul
 expens increas compar
increas due addit acquir aler busi
well higher spend area includ cardiovascular
sg expens increas compar
increas due addit acquir aler busi
well higher spend drive continu growth market expans variou
busi partial off-set lower acquisition-rel expens
first quarter result
due continu
strong growth medic
devic busi
improv perform
gross margin
compar
non-
gross margin
revenu
compar
incom expens net decreas compar
due pre-tax gain record abbott
complet sale amo johnson johnson
interest expens incom net decreas compar
due higher interest incom result higher rate return
cash cash equival short-term invest
net earn flat decreas previou year
quarter non-gaap net earn compar
ep compar
non-gaap ep increas compar
abbott oper differ segment name establish pharmaceut
product nutrit diagnost medic devic abbott gave strong
perform core busi segment total revenu
segment increas compar previou
year quarter
gaap ep
compar
continu
oper
world-wide revenu nutrit segment increas report
basi compar sale includ
favor effect foreign exchang increas organ
total revenu increas compar
previou year quarter total intern revenu increas
compar previou year quarter
world-wide pediatr nutrit revenu increas
compar previou year quarter includ favor
effect foreign exchang increas organ basi
revenu pediatr nutrit busi increas
compar previou year quarter led
strong growth across sever countri asia includ greater china
revenu increas compar
previou year quarter continu market growth led
market share gain infant nutrit categori
world-wide adult nutrit revenu increas
compar previou year quarter revenu increas
organ basi growth revenu led ensur abbott market-
lead complet balanc nutrit brand glucerna abbott
revenu adult nutrit busi increas
compar previou year quarter total revenu
 increas compar previou year
quarter
world-wide revenu
increas
report basi
compar
growth revenu
led ensur
complet balanc
nutrit brand
world-wide diagnost segment revenu increas
compar organ basi revenu
increas total revenu increas
compar previou year quarter intern revenu
increas compar previou year
laboratori diagnost revenu increas
includ favor effect foreign exchang revenu increas
organ basi reflect continu above-market growth driven
share gain intern
total core laboratori revenu increas
compar previou year quarter total intern revenu
increas compar previou year
molecular diagnost revenu increas
includ favor effect foreign exchang revenu increas
organ basi strong growth infecti diseas test
abbott core area focu molecular diagnost market partial
off-set plan scale test area primarili
total molecular diagnost revenu decreas
intern revenu increas
compar previou year quarter
point diagnost revenu increas
includ favor effect foreign exchang revenu increas
organ basi led strong intern growth abbott i-
total point care diagnost revenu
intern revenu increas compar
previou year quarter
increas
compar previou
year quarter
increas
effect foreign
rapid diagnost world-wide revenu led
infecti diseas test includ strong flu strep test volum
 total revenu intern
revenu
increas
effect foreign
establish pharmaceut revenu increas
includ favor effect foreign exchang revenu
increas organ basi
emerg market compris sever countri repres
attract long-term growth opportun abbott brand gener
product portfolio revenu geographi increas
includ favor effect foreign exchang
revenu emerg market increas organ basi
increas revenu led double-digit growth across sever
geographi includ india china brazil
increas
compar previou
year quarter
world-wide medic devic revenu increas
compar previou year quarter organ basi revenu
increas total revenu increas
compar previou year quarter total intern
revenu increas compar previou year
quarter
cardiovascular neuromodul world-wide revenu increas
compar previou year quarter total
revenu increas compar
previou year quarter total intern revenu increas
growth cardiovascular neuromodul led double-digit
growth electrophysiolog neuromodul growth
electrophysiolog includ share gain launch abbott confirm
rx insert cardiac monitor icm world first
smartphone-compat icm design help physician remot identifi
heart failur sale growth led market uptak abbott heartmat
system growth structur heart driven mitraclip abbott
market-lead devic minimally-invas treatment mitral
regurgit neuromodul strong double-digit growth led
portfolio recent launch product treatment chronic pain
diabet world-wide revenu increas
compar previou year quarter total revenu
intern revenu increas
compar previou year quarter revenu
increas organ basi
strong double-digit growth diabet care led freestyl libr
system remov need routin fingerstick peopl diabet
increas
compar previou
year quarter
growth diabet care
led freestyl
januari abbott announc fda approv magnet reson
mr -condit label quadra assura quadra assura mptm
cardiac resynchron therapi defibril crt-d devic fortifi
implant cardiovert defibril approv
abbott mr-condit label suit pacemak crt-
januari abbott announc free style libr abbott revolutionari
sensor-bas continu glucos monitor system avail
approv coverag center medicar medicaid servic
march abbott announc clinic trial data momentum studi
demonstr heartmat left ventricular assist devic
lvad improv surviv clinic outcom two year patient
advanc heart failur trial data submit fda
support consider expand current heartmat indic
fda approv master rotat mechan heart valv
first ever babi toddler
alin h-seri smaller faster integr hematolog system approv
europ
mitraclip receiv nation reimburs japan agreement
surmod next-gener drug-coat balloon
guidanc conclus
abbott project adjust ep ep
adjust ep
ep
organ sale growth forecast expect rapid
diagnost contribut sale littl
forecast adjust gross margin sale adjust
invest sale adjust sg expens sale
expect
expect ep non-gaap ep
would
abbott forecast specifi item primarili relat
initi expens
posit compani
long-term sustain
organ growth
abbott deliv strong result posit compani long-term
sustain organ growth strong perform due continu
strong growth medic devic busi improv perform
nutrit busi strong perform also due outstand
product abbott new product line abbott total revenu increas
deliv strong result posit compani long term
sustain organ growth net revenu increas due continu strong
growth medic devic busi improv perform nutrit busi
abbott total revenu increas compar
ytd stock perform roa roe abbott price-to-earnings
averag price-to-earnings multipl improv
went current expect forward price-to-earnings
multipl give buy rate stock upgrad
tp
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin ttm compar
oper margin ttm compar
y/i revenu growth ttm compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbott laboratori june
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale abbott laboratori june
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale abbott laboratori june
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item abbott laboratori june
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free june
abbott price-to-earnings averag price-to-earnings multipl improv went
current expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form daniel mile michael stephen eric thoma richard john robert brian institut holdersholdershar report outvaluevanguard group inc capit research global wellington manag compani massachusett servic northern trust price row associ well fargo top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard growth fund america spdr etf vanguard specialized-health vanguard institut fund-institut invest compani vanguard specialized-dividend appreci amcap mf seri trust i-mf valu june
developmentsabbott implement correct action heartmat heart pumpabbott notifi physician global regulatori bodi april outflow graft twist could occur post-impl heartmat lvad result persist low flow alarm may signal potenti safeti risk patient low blood flow clot devic recal patient hospit result correct action recommend made abbott remain place physician manag patient implant heartmat xienc sierra heart stent receiv nation reimburs japan treat peopl coronari arteri diseaseabbott announc thatjapan sministri health labour welfar mhlw grant nation reimburs xienc sierra newest gener compani gold-standard xienc everolimus-elut coronari stent xienc sierra improv upon previou version xienc enhanc stent design new deliveri system uniqu size help doctor treat challeng case xienc sierra design help doctor easili treat peopl difficult-to-treat blockag involv multipl total block arteri complic diabet complex case increasingli preval peopl coronari arteri diseas live longer sanquin select abbott alin solut blood plasma screeningsanquin abbottannounc sign multiple-year contract suppli primari serolog equip consum includ abbott alin system blood plasma screen agreement extend abbott sanquin long-stand relationship year fda approv world smallest mechan heart valv pediatr patient heart defectsabbott announc fda approv master rotat mechan heart valv world smallest mechan heart valv allow doctor treat babi toddler need mitral aortic valv replac till surgeon could use rang larger-s valv replac pediatr heart valv could repair larger valv often suitabl given smaller size children heart dime-s new valv first pediatr mechan heart valv develop newborn infant offer hope pediatr patient urgent need treatment approv option may june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
vs
sale growth
ttm vs industri
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit abbott laboratori june
consensu view analyst trend stock
forecast vs
abbott forward price-to-earnings
vs
abt avgfive-year growth forecast usdgrowth high day day day estim comparisonabtindustri avg avgprice/earn yield june
consensu view analyst trend stock
averag earn estim
current qtr
qtr
sale growth estim
current qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr abbott laboratori june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
stock price movement quarter volatil current trade
stock price increas march februari
annual stock perform abbott show increas trend given annual return
stock reach high
stock price volatil fell juli trade around
stock price show increas trend sinc given total return last year
abbott deliv strong perform due continu growth medic devic busi
improv perform nutrit busi maintain buy rate abbott tp
deriv target price forward look price-to-earnings ep
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
